Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes

Inherited Neuropathy Consortium

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

Here we report biallelic mutations in the sorbitol dehydrogenase gene (SORD) as the most frequent recessive form of hereditary neuropathy. We identified 45 individuals from 38 families across multiple ancestries carrying the nonsense c.757delG (p.Ala253GlnfsTer27) variant in SORD, in either a homozygous or compound heterozygous state. SORD is an enzyme that converts sorbitol into fructose in the two-step polyol pathway previously implicated in diabetic neuropathy. In patient-derived fibroblasts, we found a complete loss of SORD protein and increased intracellular sorbitol. Furthermore, the serum fasting sorbitol levels in patients were dramatically increased. In Drosophila, loss of SORD orthologs caused synaptic degeneration and progressive motor impairment. Reducing the polyol influx by treatment with aldose reductase inhibitors normalized intracellular sorbitol levels in patient-derived fibroblasts and in Drosophila, and also dramatically ameliorated motor and eye phenotypes. Together, these findings establish a novel and potentially treatable cause of neuropathy and may contribute to a better understanding of the pathophysiology of diabetes.

Original languageEnglish (US)
Pages (from-to)473-481
Number of pages9
JournalNature Genetics
Volume52
Issue number5
DOIs
StatePublished - May 1 2020

Bibliographical note

Funding Information:
This project was supported by the NINDS (R01NS075764 to S.Z. and M.S.; R01NS105755 to S.Z.), the NIH (R21GM119018 and 1R61AT010408 to R.G.Z.), the NCATS (U54NS065712 to M.S.), the CMT Association, the Hereditary Neuropathy Foundation, The Genesis Project foundation, the Muscular Dystrophy Association, the European Union’s Horizon 2020 research and innovation programme under the ERA-NET Cofund action no. 643578 under the frame of the E-Rare-3 network PREPARE (01GM1607 to M.S.; and unfunded to S.Z.), the grant 779257 ‘Solve-RD’ (to R.S. and M.S., M.M.R. and H.H.) and the National Institute for Health Research University College London Hospitals Biomedical Research Centre (to M.L.). The project received further support from the ‘Bundesministerium für Bildung und Forschung’ (BMBF) via funding for the TreatHSP consortium (01GM1905 to R.S.) and the National Institutes of Health (grant 5R01NS072248 to R.S. and S.Z.), the Austrian Science Fund (FWF, P27634FW to M.A.-G.) and the National Natural Science Foundation of China (81771366). A.C. thanks the Medical Research Council (MR/T001712/1), the Wellcome Trust (204841/Z/16/Z), the Fondazione CARIPLO (2019-1836), the Italian Ministry of Health Ricerca Corrente 2018–2019 and the Inherited Neuropathy Consortium (INC) for grant support. H.H. and M.M.R. thank the MRC, the Wellcome Trust, the MDA, MD UK, Ataxia UK, The MSA Trust, the Rosetrees Trust and the NIHR UCLH BRC for grant support. A.M.R. is funded by a Wellcome Trust Postdoctoral Fellowship for Clinicians (110043/Z/15/Z). D.N.H. receives grant support through NIH U54 NS065712-09, the Muscular Dystrophy Association, the Friedreich’s Ataxia Alliance and Voyager Pharmaceuticals. We thank M. Tekin for kindly providing DNA from healthy controls or Turkish ancestry. We also thank Twenty Three Calvin (Marie Stargala and Matthew Rosen) for creating the cover art for the issue.

Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.

Fingerprint Dive into the research topics of 'Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes'. Together they form a unique fingerprint.

Cite this